Want to see SYRE full AI Analyst Report?
Top Page
Spyre Therapeutics
(NASDAQ:SYRE)
Select Model
Select Model
Rating:54Neutral
Price Target:
$91.00
▼(-15.24% Downside)
Action:Reiterated
Date:09/08/26
The score is anchored by strong capitalization with zero debt but is held back by substantial ongoing losses and cash burn. Technicals add near-term risk given weak momentum and below-key moving averages. Offsetting some of this, corporate events are a meaningful positive due to multiple encouraging Phase 2 readouts, while valuation remains challenged because profitability is negative and there is no dividend support.
Positive Factors
Phase 2 IBD proof-of-concept
Positive Phase 2 results across SPY001, SPY002, and SPY003 provide clinical proof-of-concept for the company’s three IBD mechanisms. This broadens the development base and supports testing combination regimens that could strengthen Spyre’s product strategy over the next several quarters.
Negative Factors
High cash burn
Large negative operating and free cash flow show that Spyre is not yet self-funding its operations. Continued clinical investment therefore depends on its available capital and future financing capacity, which can constrain flexibility if development spending remains elevated.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 2 IBD proof-of-concept
Positive Phase 2 results across SPY001, SPY002, and SPY003 provide clinical proof-of-concept for the company’s three IBD mechanisms. This broadens the development base and supports testing combination regimens that could strengthen Spyre’s product strategy over the next several quarters.
Read all positive factors
Spyre Therapeutics (SYRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.82B
Dividend YieldN/A
Average Volume (3M)986.60K
Price to Earnings (P/E)―
Beta (1Y)1.92
Revenue GrowthN/A
EPS Growth28.51%
CountryUS
Employees125
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.95
Shares Outstanding88,173,760
10 Day Avg. Volume1,124,926
30 Day Avg. Volume986,599
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.93
Price to Sales (P/S)0.00
P/FCF Ratio-12.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$122.73Price Target Upside14.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.74
Revenue Forecast (FY)N/A
Spyre Therapeutics Business Overview & Revenue Model
Company Description
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human mono...
How the Company Makes Money
Spyre Therapeutics is a clinical-stage biotech company, and its ability to generate recurring product revenue depends on successfully developing and commercializing approved therapeutics. As of the latest publicly available information, the compan...
Spyre Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 90.49M | 0.00 | 0.00 | 886.00K | 2.33M | 18.74M |
| Gross Profit | 0.00 | -171.65M | 0.00 | 886.00K | 2.33M | 18.74M |
| EBITDA | -185.55M | -209.56M | -207.97M | -127.60M | -81.99M | -64.08M |
| Net Income | -178.92M | -155.20M | -208.02M | -338.79M | -83.81M | -65.80M |
Balance Sheet | ||||||
| Total Assets | 1.17B | 777.78M | 608.48M | 341.86M | 71.14M | 109.93M |
| Cash, Cash Equivalents and Short-Term Investments | 1.15B | 756.53M | 603.09M | 339.28M | 55.71M | 93.13M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 4.63M | 5.06M |
| Total Liabilities | 71.86M | 62.55M | 90.68M | 157.84M | 20.84M | 25.98M |
| Stockholders Equity | 1.10B | 715.24M | 517.80M | 184.02M | 50.30M | 83.94M |
Cash Flow | ||||||
| Free Cash Flow | -208.94M | -169.25M | -157.41M | -99.91M | -80.18M | -54.29M |
| Operating Cash Flow | -208.94M | -169.25M | -157.41M | -99.91M | -80.14M | -53.72M |
| Investing Cash Flow | -463.74M | -143.47M | -353.29M | -108.39M | 57.01M | -22.62M |
| Financing Cash Flow | 753.03M | 309.02M | 410.91M | 361.08M | 42.68M | 1.39M |
Spyre Therapeutics Technical Analysis
Positive
107.36
Price Trends
98.10
Negative
87.54
Positive
63.29
Positive
Market Momentum
-3.26
Positive
42.76
Neutral
52.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRE, the sentiment is Positive. The current price of 107.36 is above the 20-day moving average (MA) of 96.45, above the 50-day MA of 98.10, and above the 200-day MA of 63.29, indicating a neutral trend. The MACD of -3.26 indicates Positive momentum. The RSI at 42.76 is Neutral, neither overbought nor oversold. The STOCH value of 52.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRE.
Spyre Therapeutics Risk Analysis
Spyre Therapeutics disclosed 73 risk factors in its most recent earnings report. Spyre Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Spyre Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $9.45B | -25.84 | -34.15% | ― | -100.00% | -5.32% | |
54 Neutral | $7.82B | -46.46 | -24.32% | ― | ― | 28.51% | |
52 Neutral | $696.56M | -6.16 | -42.92% | ― | ― | 34.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $314.93M | -1.98 | -48.40% | ― | 15.98% | -40.75% | |
46 Neutral | $503.20M | -2.18 | -256.67% | ― | 4.08% | -343.67% | |
44 Neutral | $366.40M | -1.13 | -135.81% | ― | -94.63% | -39.78% |
* Healthcare Sector Average
SYRE
Spyre Therapeutics
90.60
74.95
478.91%
EYPT
EyePoint Pharmaceuticals
4.23
-9.12
-68.31%
PRAX
Praxis Precision Medicines
334.58
296.88
787.48%
SPRY
ARS Pharmaceuticals
4.76
-5.27
-52.54%
OCS
Oculis Holding
10.56
-6.84
-39.31%
UPB
Upstream Bio, Inc.
5.73
-11.84
-67.39%
Spyre Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Spyre Therapeutics Reports Positive Phase 2 SKYLINE Data
Positive
Sep 8, 2026
On September 8, 2026, Spyre Therapeutics reported positive 12-week induction topline data from Part A of its Phase 2 SKYLINE trial, evaluating SPY003, an extended half-life anti-IL-23 antibody for moderately-to-severely active ulcerative colitis. ...
Business Operations and StrategyProduct-Related Announcements
Spyre Therapeutics reports Phase 2 TL1A trial results
Positive
Aug 25, 2026
On August 25, 2026, Spyre Therapeutics reported topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072, showing both tested doses achieved statistically significant benefits versus placeb...
Business Operations and StrategyProduct-Related Announcements
Spyre Therapeutics Reports Strong Phase 2 SKYLINE Results
Positive
Jun 15, 2026
On June 15, 2026, Spyre Therapeutics reported positive 12-week induction topline results from Part A of its Phase 2 SKYLINE trial evaluating SPY002, an extended half-life anti-TL1A antibody, in moderately to severely active ulcerative colitis. In ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.